Immunostaining to c-IAP-2 appeared in the cytoplasm of basal (normal and BPH) or secretory (cancer) epithelial cells in 60% of normal prostates (figure 2A), 57.57% of patients with BPH (figure 2B, Table 1), 55.15% of patients with PIN and in 40% of PC patients (figure 2C and Table 1). Here, BIRC3 is linked to prostate intraepithelial neoplasia.